JW reports the number of HCPCS billing units of a Part B drug that were discarded from a single-dose container after the patient was dosed. It goes on a separate claim line from the administered dose — never on the same line as JZ — and is required by CMS on every single-dose-vial claim where any drug was wasted. Since July 1, 2023, the companion JZ modifier is required when zero drug was discarded; one of the two must appear on every single-dose-container line.
JW is defined in CMS Internet-Only Manual Publication 100-04 (Medicare Claims Processing Manual), Chapter 17, §40 (Discarded Drugs and Biologicals). The statutory hook is Section 90004 of the Infrastructure Investment and Jobs Act, which directs CMS to recover refunds from manufacturers for unused single-dose-container drug. JW is the data-capture mechanism that produces those refund calculations.
JW reporting on Medicare Part B has been mandatory since January 1, 2017 (Change Request 9603). The companion JZ modifier was introduced by CMS Transmittal R11603CP / Change Request 12056, effective July 1, 2023, with edit-cycle enforcement starting October 1, 2023. The effect is that every single-dose container line submitted to Medicare from October 2023 forward must carry either JW (drug discarded) or JZ (no drug discarded). A line that carries neither will reject; a line that carries both will reject as a mutually exclusive modifier pair.
The decision tree is deliberately mechanical because the underlying refund calculation is also mechanical: CMS aggregates JW data quarterly to compute manufacturer refund liability under the Infrastructure Investment and Jobs Act formula, and ambiguous coding undermines the audit trail. In practice, the most common scenario for JW is a body-surface-area (BSA) or weight-based dose that does not divide evenly into vial sizes — oncology biologics like Abraxane, Avastin, Herceptin, and Rituxan generate JW lines on the majority of administrations because the dose-per-vial-size ratio almost never lands exactly. Fixed-dose drugs like Keytruda 200 mg flat dose, by contrast, generate JZ on nearly every administration because two 100 mg vials hit the dose exactly.
The single largest source of JW denials is misuse on multi-dose vials. Acthar Gel, Sandostatin LAR depot kits, and several insulins ship as MDVs and do not generate a JW reporting obligation regardless of residual volume. Read the label on the actual vial drawn, not the practice's expectation.
Medicare Part B is the source of truth for JW/JZ. Commercial payers have largely aligned to the CMS convention, though enforcement strictness and audit posture vary. UnitedHealthcare has the most aggressive post-payment audit program for JW data integrity; the other commercials warn-and-pass on minor mismatches more often than Medicare or UHC.
| Payer | JW required on SDV waste? | Notes |
|---|---|---|
| Medicare (Part B) | Yes — rejects without JW or JZ | Source-of-truth payer. Edit cycle enforces both modifiers since 10/1/2023. Quarterly JW data feeds manufacturer-refund calculations under IIJA §90004. MACs have published LCDs reiterating the IOM Ch.17 §40 rule verbatim. |
| UnitedHealthcare | Yes | Aligns with CMS at adjudication. Adds a post-payment audit overlay that flags JW lines whose units exceed 25% of the administered amount for a documentation request. Specialty drugs going through OptumRx infused-meds management also need the JW reflected on the prior-auth approval if dose changed. |
| Aetna (CVS Health) | Yes | Aligns with CMS. Aetna's medical-policy bulletins for oncology drugs explicitly reference IOM Ch.17 §40. CVS Specialty pre-filled syringes do not generate JW. |
| Cigna / Express Scripts | Yes | Aligns with CMS. Accredo dispensing reports include JW-equivalent waste data on the dispensing report; the practice still bills JW on the buy-and-bill medical claim where applicable. |
| Humana | Yes | MA-heavy book follows CMS by default. CenterWell Specialty pre-filled and pre-mixed product does not generate JW. Humana commercial commercial-PPO has the same alignment with a slightly later edit-cycle enforcement than Medicare. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| Missing JW when drug discarded (CARC 16 / RARC N822) | Single-dose container claim shows a partial-vial administered amount but no JW line for the wasted units. Medicare reads this as either underreporting waste or a multi-dose-vial misidentification. | Resubmit with a second line for the discarded units carrying JW. Appeal language: “Per CMS IOM Pub 100-04, Chapter 17, §40, the original claim should have included a separate line for the discarded units of [J-code] with modifier JW. The corrected claim reflects [X] administered units on the original line and [Y] discarded units on a new line with JW, matching the [Z] total billing units of the single-dose container(s) opened.” |
| JW + JZ on same line (mutually exclusive) | Both modifiers appended to one line. JW and JZ describe opposite scenarios (discarded vs no discard) and cannot coexist on a single line. | Resubmit with the correct single modifier. If any waste occurred, use two lines: administered (no modifier) + discarded (JW). If no waste, use one line with JZ. Appeal language: “CMS Transmittal R11603CP defines JW and JZ as mutually exclusive. The corrected claim removes the inappropriate modifier and structures the line(s) per IOM Pub 100-04, Chapter 17, §40.” |
| JW on multi-dose vial | JW appended to a line for a drug supplied in a container labeled “Multi-Dose” or “MDV.” Multi-dose vials do not generate a JW reporting obligation regardless of residual. | Resubmit without JW (and without JZ). Appeal language: “Per CMS IOM Pub 100-04, Chapter 17, §40, JW applies only to single-dose containers as defined by FDA labeling. The product administered is supplied in a multi-dose vial (NDC [X], FDA label designation: Multi-Dose), so no waste modifier is required.” Attach the FDA package insert page showing the MDV designation. |
| JW on biosimilar with wrong base code | JW was reported with the reference-product J-code (e.g., J9312 for Rituxan) when the drug actually administered was a biosimilar with its own HCPCS (e.g., Q5117 for Riabni). The modifier is correct but the base code is wrong. | Resubmit with the biosimilar HCPCS code on both the administered line and the JW waste line. Appeal language: “The product administered was [biosimilar name], NDC [X], reportable under HCPCS [Q-code]. JW reporting rules per IOM Pub 100-04, Chapter 17, §40 apply identically to biosimilars; the corrected claim uses the biosimilar HCPCS on both the administered and the JW waste line, with integer units summing to the vial-equivalent total.” |
| Non-integer JW units | JW line submitted with a fractional unit count (e.g., “7.5 units”). Medicare Part B requires whole-number HCPCS units. | Round at the line level so that administered units + JW units = the total billing units of all single-dose containers opened. Document the underlying milligram math in the medical record. Resubmit both lines with integer units. Appeal language: “The corrected claim reports integer HCPCS units on both lines such that the sum (administered + JW) equals the total billing units of the [N] single-dose containers opened. The fractional milligram calculation is preserved in the chart per CMS documentation guidance.” |
JW reports the units of drug discarded from a single-dose container when there was leftover. JZ attests that zero drug was discarded from a single-dose container. The two are mutually exclusive on a single claim line and are mandatory complements: every single-dose container line must carry one or the other, never both, never neither.
JW reporting on Medicare Part B single-dose container claims has been required since January 1, 2017, per CR 9603. The companion JZ modifier became required effective July 1, 2023, per CMS Transmittal R11603CP (CR 12056), with the edit cycle enforcing rejections beginning October 1, 2023.
A single-dose container is a vial, ampule, bottle, or other container of an injectable drug or biological intended for use by a single patient on one occasion. FDA labeling controls the designation: containers labeled “Single-Dose,” “Single-Use,” “SDV,” or “SDC” qualify. The FDA package insert is the authoritative source — not the in-house policy of the practice.
No. JW and JZ are exclusive to single-dose containers. Multi-dose vials (MDVs) — those labeled “Multi-Dose” or “MDV” — do not require either modifier, even if some drug remains in the vial after the patient encounter. Appending JW to an MDV line is a top-five denial trigger.
JW reporting rules are identical for biosimilars: if the biosimilar is supplied in a single-dose container, JW is required on a separate line for any discarded units, and JZ is required on the administered line if no waste occurred. The biosimilar HCPCS code (e.g., Q5117 for Riabni) replaces the reference J-code, but the modifier convention does not change.
FDA labeling for single-dose containers does not authorize multi-patient use. Some hospital systems do vial-share under USP 797 sterile-compounding rules within a six-hour beyond-use date, but for Medicare billing each patient's claim still reports the units administered with JZ (no waste from that patient's perspective). The vial-share scenario does not create a JW reporting obligation because no drug was discarded — it was administered to a second patient.
Medicare Part B requires whole-number units on HCPCS J-code billing. Fractional units are rejected. The JW line reports the rounded number of HCPCS billing units of discarded drug; if your dose math yields a fractional remainder, document the calculation in the medical record but report integer units on both the administered and JW lines such that the sum equals the total vial-equivalent units drawn.
The administered units + JW units must equal the total billing units of the single-dose containers opened — typically a whole-vial multiple. If you opened two 100 mg vials and administered 160 mg, the line totals should add to 200 mg (or the equivalent billing units). A mismatch between vial-equivalent units and the sum of administered + JW is the second most common JW denial.
All sources are publicly available federal publications or paraphrased from trade-association educational materials. The methodology by which we resolve source disagreements is described in the Methodology.